The Role of the Heat-Shock Proteins in Esophagogastric Cancer

Imagem de Miniatura
Arquivos
art_TUSTUMI_The_Role_of_the_HeatShock_Proteins_in_Esophagogastric_2022.PDF (1.33 MB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
AGARENO, Gabriel Andrade
GALLETTI, Ricardo Purchio
SILVA, Rafael Benjamim Rosa da
QUINTAS, Julia Grams
SESCONETTO, Lucas de Abreu
WOLOSKER, Nelson
Citação
CELLS, v.11, n.17, article ID 2664, 13p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Heat-shock proteins (HSPs) are a family of proteins that have received considerable attention over the last several years. They have been classified into six prominent families: high-molecular-mass HSP, 90, 70, 60, 40, and small heat shock proteins. HSPs participate in protein folding, stability, and maturation of several proteins during stress, such as in heat, oxidative stress, fever, and inflammation. Due to the immunogenic host's role in the combat against cancer cells and the role of the inflammation in the cancer control or progression, abnormal expression of these proteins has been associated with many types of cancer, including esophagogastric cancer. This study aims to review all the evidence concerning the role of HSPs in the pathogenesis and prognosis of esophagogastric cancer and their potential role in future treatment options. This narrative review gathers scientific evidence concerning HSPs in relation to esophagus and gastric cancer. All esophagogastric cancer subtypes are included. The role of HSPs in carcinogenesis, prognostication, and therapy for esophagogastric cancer are discussed. The main topics covered are premalignant conditions for gastric cancer atrophic gastritis, Barrett esophagus, and some viral infections such as human papillomavirus (HPV) and Epstein-Barr virus (EBV). HSPs represent new perspectives on the development, prognostication, and treatment of esophagogastric cancer.
Palavras-chave
heat-shock proteins, esophageal neoplasm cancers, stomach neoplasm
URI
https://observatorio.fm.usp.br/handle/OPI/49464
Referências
  1. Albakova Z, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.660085
  2. Albakova Z, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2020.100995
  3. Ando K, 2014, GASTRIC CANCER, V17, P255, DOI 10.1007/s10120-013-0279-1
  4. Arnold M, 2019, LANCET ONCOL, V20, P1493, DOI 10.1016/S1470-2045(19)30456-5
  5. Aswad A, 2021, ADV CANCER RES, V152, P179, DOI 10.1016/bs.acr.2021.03.006
  6. Bepperling A, 2012, P NATL ACAD SCI USA, V109, P20407, DOI 10.1073/pnas.1209565109
  7. Berezowska S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069098
  8. Birbo B, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910317
  9. Bognar L, 2018, INFECT AGENTS CANCER, V13, DOI 10.1186/s13027-018-0210-9
  10. Calderwood SK, 2016, TRENDS BIOCHEM SCI, V41, P311, DOI 10.1016/j.tibs.2016.01.003
  11. Calil IL, 2022, EINSTEIN-SAO PAULO, V20, DOI [10.31744/einstein_journal/2022RB6181, 10.31744/einstein_journal/2022rb6181]
  12. Carrasco V, 2011, VET PATHOL, V48, P322, DOI 10.1177/0300985810375050
  13. Chawla A, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00074
  14. Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1
  15. Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096
  16. Dargiene G, 2018, J GASTROINTEST LIVER, V27, P363, DOI 10.15403/jgld.2014.1121.274.tlr
  17. De Maio A, 2012, CELL STRESS CHAPERON, V17, P139, DOI 10.1007/s12192-012-0320-z
  18. Deng WJ, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0283-8
  19. Dolcetti R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061602
  20. Dubrez L, 2020, ONCOGENE, V39, P516, DOI 10.1038/s41388-019-1016-y
  21. Dutta SM, 2014, ENVIRON MONIT ASSESS, V186, P8961, DOI 10.1007/s10661-014-4057-2
  22. Faried A, 2004, EUR J CANCER, V40, P2804, DOI 10.1016/j.ejca.2004.08.013
  23. Farkas R, 2011, ANTICANCER RES, V31, P1769
  24. Fukagawa Y, 2008, ELECTROPHORESIS, V29, P3192, DOI 10.1002/elps.200800086
  25. Garcia-Carbonero R, 2013, LANCET ONCOL, V14, pE358, DOI 10.1016/S1470-2045(13)70169-4
  26. gco.iarc.fr, GLOBAL CANC OBSERVAT
  27. Goyal L, 2020, INVEST NEW DRUG, V38, P1533, DOI 10.1007/s10637-019-00889-y
  28. Guo LW, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005318
  29. Hamel C, 2020, SYST REV-LONDON, V9, DOI 10.1186/s13643-020-1275-2
  30. Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
  31. Hao Y, 2012, POULTRY SCI, V91, P781, DOI 10.3382/ps.2011-01627
  32. Kapranos N, 2002, J CANCER RES CLIN, V128, P426, DOI 10.1007/s00432-002-0357-y
  33. Kattaia A.A.A.A., 2018, HEAT SHOCK PROTEINS, P127
  34. Kawanishi K, 1999, CANCER, V85, P1649, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1649::AID-CNCR2>3.0.CO;2-V
  35. Killock D, 2022, NAT REV CLIN ONCOL, V19, P150, DOI 10.1038/s41571-021-00594-x
  36. Langer R, 2011, MODERN PATHOL, V24, P908, DOI 10.1038/modpathol.2011.52
  37. Langer R, 2008, CLIN CANCER RES, V14, P8279, DOI 10.1158/1078-0432.CCR-08-0679
  38. Latchford A, 2004, SPR SP SURG SER, P259
  39. Lee YT, 2018, EUR J PHARMACOL, V834, P188, DOI 10.1016/j.ejphar.2018.07.034
  40. Li YY, 2009, DRUG RESIST UPDATE, V12, P17, DOI 10.1016/j.drup.2008.12.002
  41. Liu WL, 2007, ACTA PHARMACOL SIN, V28, P1001, DOI 10.1111/j.1745-7254.2007.00589.x
  42. Malone ER, 2020, GENOME MED, V12, DOI 10.1186/s13073-019-0703-1
  43. Matsui HM, 2021, CANCER IMMUNOL IMMUN, V70, P945, DOI 10.1007/s00262-020-02737-y
  44. Mauchley D, 2010, J THORAC CARDIOV SUR, V139, P1019, DOI 10.1016/j.jtcvs.2009.09.066
  45. Meng L, 2011, ONCOGENE, V30, P2836, DOI 10.1038/onc.2011.5
  46. Nagata Y, 2013, DIGEST DIS SCI, V58, P381, DOI 10.1007/s10620-012-2342-x
  47. Nakajima M, 2002, CANCER LETT, V178, P99, DOI 10.1016/S0304-3835(01)00825-4
  48. Nakamoto H, 2007, CELL MOL LIFE SCI, V64, P294, DOI 10.1007/s00018-006-6321-2
  49. Neckers L, 2007, J BIOSCIENCES, V32, P517, DOI 10.1007/s12038-007-0051-y
  50. Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000
  51. Noguchi T, 2002, ANN THORAC SURG, V74, P222, DOI 10.1016/S0003-4975(02)03641-X
  52. O'Donnell JS, 2019, CLIN CANCER RES, V25, P5743, DOI 10.1158/1078-0432.CCR-18-2641
  53. Rafiee P, 2006, AM J PHYSIOL-CELL PH, V291, pC931, DOI 10.1152/ajpcell.00474.2005
  54. Rajendra S, 2020, ANN NY ACAD SCI, V1482, P36, DOI 10.1111/nyas.14509
  55. RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188
  56. Rodriguez-Iturbe B, 2018, PHYSIOL INT, V105, P19, DOI 10.1556/2060.105.2018.1.4
  57. Shehata AM, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10122407
  58. Shevtsov M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00171
  59. Shimizu Y, 2019, CANCER SCI, V110, P3049, DOI 10.1111/cas.14165
  60. Shiozaki H, 2000, SURGERY, V127, P552, DOI 10.1067/msy.2000.105028
  61. Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
  62. Skoie IM, 2022, CLIN EXP DERMATOL, V47, P1068, DOI 10.1111/ced.15068
  63. Slotta-Huspenina J, 2014, CANCERS, V6, P1382, DOI 10.3390/cancers6031382
  64. Soderstrom HK, 2019, WORLD J CLIN CASES, V7, P260, DOI 10.12998/wjcc.v7.i3.260
  65. Solarova Z, 2015, INT J ONCOL, V46, P907, DOI 10.3892/ijo.2014.2791
  66. Stogbauer L, 2020, NEUROSURG REV, V43, P903, DOI 10.1007/s10143-019-01087-3
  67. Subbiah V, 2018, TRENDS CANCER, V4, P101, DOI 10.1016/j.trecan.2017.12.004
  68. [孙蕾民 SUN Lei-min], 2009, [中华消化杂志, Chinese Journal of Digestion], V29, P164
  69. Tavakoli A, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07013-x
  70. Farinha HT, 2022, CANCERS, V14, DOI 10.3390/cancers14030554
  71. Troian M., 2020, J GASTRIC SURG, V2, P79, DOI [10.36159/JGS.V2I3.56, DOI 10.36159/JGS.V2I3.56]
  72. Tustumi F., 2022, RADIOL BRAS, V1, P1, DOI [10.1590/0100-3984.2021.0135, DOI 10.1590/0100-3984.2021.0135]
  73. Tustumi F, 2016, ABCD-ARQ BRAS CIR DI, V29, P138, DOI 10.1590/0102-6720201600030003
  74. Vesci L, 2014, INT J ONCOL, V45, P1421, DOI 10.3892/ijo.2014.2575
  75. Wang XP, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/212537
  76. Wang XT, 2014, BIOCHEM BIOPH RES CO, V452, P945, DOI 10.1016/j.bbrc.2014.09.026
  77. Wu JM, 2017, TRENDS PHARMACOL SCI, V38, P226, DOI 10.1016/j.tips.2016.11.009
  78. Xi CX, 2012, J BIOL CHEM, V287, P35646, DOI 10.1074/jbc.M112.377481
  79. Yamamoto S, 2020, FUTURE ONCOL, V16, P1351, DOI 10.2217/fon-2020-0189
  80. Yun CW, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010060
  81. Zhai ET, 2018, CELL PHYSIOL BIOCHEM, V47, P879, DOI 10.1159/000490080
  82. Zhang KC, 2017, J CANCER, V8, P1826, DOI 10.7150/jca.18946
  83. Zhang Q, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.532403
  84. Zhang RG, 2012, ASIAN PAC J CANCER P, V13, P2185, DOI 10.7314/APJCP.2012.13.5.2185
  85. Zhang X, 2020, ONCOL REP, V44, P1355, DOI 10.3892/or.2020.7711
  86. Zhang YM, 2020, CLIN EXP RHEUMATOL, V38, P1191
  87. Zhao P, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00030
  88. Zheng CX, 2011, CHINESE MED J-PEKING, V124, P2347, DOI 10.3760/cma.j.issn.0366-6999.2011.15.018
  89. Zininga T, 2018, MOLECULES, V23, DOI 10.3390/molecules23112846
  90. Zoltan L, 2019, PATHOL ONCOL RES, V25, P279, DOI 10.1007/s12253-017-0342-z

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - LIM/35
Artigos e Materiais de Revistas Científicas - ODS/03